Garsorasib in KRAS G12C-Mutated Non-Small-Cell Lung Cancer: Updated Results from a Phase 2 Study

被引：0

作者：

Li, Z. ^{[1
]}

Lu, S. ^{[1
]}

Dang, X. ^{[2
]}

Huang, D. ^{[3
]}

Jin, S. ^{[4
,5
]}

Li, W. ^{[6
]}

Shi, J. ^{[7
]}

Wang, X. ^{[8
,21
]}

Zhang, Y. ^{[9
]}

Song, Z. ^{[9
]}

Zhang, J. ^{[10
]}

Zhuang, W. ^{[11
]}

Liu, X. ^{[12
]}

Jiang, L. ^{[1
]}

Meng, X. ^{[13
]}

Zhao, M. ^{[14
]}

Zhou, J. ^{[15
]}

Zhang, L. ^{[16
,44
]}

Wang, P. ^{[17
]}

Luo, H. ^{[18
]}

Yang, J. ^{[19
]}

Cang, S. ^{[20
]}

Wang, X. ^{[8
,21
]}

Wang, J. ^{[22
]}

Cui, J. ^{[23
]}

Yu, Y. ^{[24
]}

Zhang, Z. ^{[25
]}

Lu, J. ^{[26
]}

Yang, W. ^{[27
]}

Li, G. ^{[28
]}

Feng, J. ^{[29
]}

Lv, D. ^{[30
]}

Wu, L. ^{[31
]}

Fang, Y. ^{[32
]}

Wang, Y. ^{[33
]}

Zhao, Y. ^{[34
]}

Cao, B. ^{[35
]}

Zhu, W. ^{[36
]}

Zhuang, Z. ^{[37
]}

Li, Q. ^{[38
]}

Wang, M. ^{[39
]}

Zhou, H. ^{[39
]}

Dong, X. ^{[40
]}

Hu, S. ^{[41
]}

Fang, J. ^{[42
]}

Xu, C. -W. ^{[43
]}

Wang, W. ^{[44
]}

Xiang, Z. ^{[44
]}

Shi, Z. ^{[44
]}

Zhang, L. ^{[16
,44
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[4] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Shenzhen, Peoples R China

[5] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China

[6] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China

[8] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[9] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China

[10] Shanxi Med Univ, Affiliated Bethune Hosp, Taiyuan, Peoples R China

[11] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[12] Cent South Univ, Xiangya Hosp 3, Changsha, Peoples R China

[13] Shandong Canc Hosp, Jinan, Peoples R China

[14] China Med Univ, Hosp 1, Shenyang, Peoples R China

[15] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[16] Yantai Yuhuangding Hosp, Yantai, Peoples R China

[17] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China

[18] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[19] Tangshan Canc Hosp, Tangshan, Peoples R China

[20] Henan Prov Peoples Hosp, Zhengzhou, Peoples R China

[21] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China

[22] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China

[23] First Hosp Jilin Univ, Changchun, Peoples R China

[24] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[25] Anhui Prov Canc Hosp, Hefei, Peoples R China

[26] Nantong Tumor Hosp, Nantong, Peoples R China

[27] Shanxi Canc Hosp, Taiyuan, Peoples R China

[28] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[29] Jiangsu Canc Hosp, Nanjing, Peoples R China

[30] Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China

[31] Hunan Canc Hosp, Changsha, Peoples R China

[32] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China

[33] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China

[34] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[35] Peking Univ Third Hosp, Beijing, Peoples R China

[36] Baotou Cent Hosp, Baotou, Peoples R China

[37] Soochow Univ, Affiliated Hosp 2, Suzhou, Peoples R China

[38] Chengde Med Univ, Affiliated Hosp, Chengde, Peoples R China

[39] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China

[40] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[41] Hubei Canc Hosp, Wuhan, Peoples R China

[42] Beijing Canc Hosp, Beijing, Peoples R China

[43] Nanjing Univ, Sch Med, Jinling Hosp, Nanjing, Peoples R China

[44] InventisBio Co Ltd, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

Non-small-cell; Lung Cancer; KRAS G12C mutation; Phase; 2; study;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA14.03

引用

页码：S40 / S41

页数：2

共 50 条

[21] Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Skoulidis, Ferdinandos
Li, Bob T.
Hochmair, Maximilian
Govindan, Ramaswamy
Vincent, Mark
van der Wekken, Anthonie J.
Reguart Aransay, Noemi
O'Byrne, Kenneth J.
Girard, Nicolas
Griesinger, Frank
Nishio, Makoto
Haefliger, Simon
Lindsay, Colin
Reinmuth, Niels
Paulus, Astrid
Papakotoulas, Pavlos
Kim, Sang-We
Ferreira, Carlos Gil
Pasello, Giulia
Duruisseaux, Michael
Gennatas, Spyridon
Dimou, Anastasios
Mehta, Bhakti
Kormany, William
Nduka, Chidozie
Sylvester, Brooke E.
Ardito-Abraham, Christine
Wang, Yang
de Langen, Adrianus Johannes
ONCOLOGIST, 2025, 30 (01):
[22] Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Luiz Henrique Araujo
Bianca Mendes Souza
Laura Rabelo Leite
Sabrina A. F. Parma
Natália P. Lopes
Frederico S. V. Malta
Maíra C. M. Freire
BMC Cancer, 21
[23] Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Araujo, Luiz Henrique
Souza, Bianca Mendes
Leite, Laura Rabelo
Parma, Sabrina A. F.
Lopes, Natalia P.
Malta, Frederico S. V.
Freire, Maira C. M.
BMC CANCER, 2021, 21 (01)
[24] Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
Iska, Sindu
Alley, Evan W.
CASE REPORTS IN ONCOLOGY, 2023, 16 (01): : 183 - 187
[25] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer
Tsurutani, J.
Park, H.
Doi, T.
Modi, S.
Takahashi, S.
Nakagawa, K.
Krop, I.
Waqar, S.
Yoh, K.
Li, B.
Taira, S.
Jikoh, T.
Singh, J.
Sugihara, M.
Janne, P.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S324 - S324
[26] COST PER RESPONDER ANALYSIS COMPARING ADAGRASIB AND SOTORASIB IN PATIENTS WITH KRAS G12C-MUTATED PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC)
Berardi, A.
Laurie, M.
Theriou, C.
Orsini, I
Bouwmeester, W.
Gao, S.
Korytowsky, B.
VALUE IN HEALTH, 2023, 26 (12) : S119 - S120
[27] KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study
Zhou, Q.
Meng, X.
Sun, L.
Huang, D.
Yang, N.
Yu, Y.
Zhao, M.
Zhuang, W.
Hu, Y.
Pan, Y.
Sun, M.
Shan, J.
Guo, R.
Chu, Q.
Xu, C.
Lin, J.
Huang, J.
Huang, M.
Zhang, S.
Wu, Y. L.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S42 - S42
[28] Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Yamada, T.
Morimoto, K.
Hirai, S.
Katayama, Y.
Kunimasa, K.
Sasaki, T.
Nishida, M.
Watanabe, S.
Shiotsu, S.
Uehara, H.
Takayama, K.
ANNALS OF ONCOLOGY, 2023, 34 : S194 - S194
[29] Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
Wislez, M.
Mascaux, C.
Cadranel, J.
Thomas, Q. D.
Ricordel, C.
Swalduz, A.
Pichon, E.
Veillon, R.
Gounant, V.
Rousseau-Bussac, G.
Madroszyk, A.
Daniel, C.
Ravoire, M.
Metivier, A. -C
Fournel, P.
Missy, P.
Morin, F.
Guisier, F.
Westeel, V.
EUROPEAN JOURNAL OF CANCER, 2025, 219
[30] Clinical Characteristics and Outcomes in Patients With KRAS G12C Mutated Non-Small Cell Lung Cancer
Pellini, B.
Ganesan, V.
Wan, F.
Sankararaman, S.
Manyanont, S.
Akhave, N.
Baggstrom, M.
Ward, J.
Waqar, S.
Morgensztern, D.
Govindan, R.
Devarakonda, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S209 - S210

← 1 2 3 4 5 →